November 2, 2012Open Access

Immunoreactivity Score Using an Anti-sst2A Receptor Monoclonal Antibody Strongly Predicts the Biochemical Response to Adjuvant Treatment with Somatostatin Analogs in Acromegaly

Key Points

Key points are not available for this paper at this time.

Abstract

Sst2A IRS with the anti-sst2A antibody UMB-1 represents a valid tool in the clinical practice to identify acromegalic patients likely to be responders to adjuvant therapy with the currently available somatostatin analogs.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Gatto et al. (Fri,) studied this question.

synapsesocial.com/papers/69daa8f03bc1ef722568475e https://doi.org/https://doi.org/10.1210/jc.2012-2609

Bookmark

View Full Paper